• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Long-Term Treatment Response in Pediatric OCD

Long-Term Treatment Response in Pediatric OCD

March 12, 2021
Pavan Madan, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pavan Madan, MD Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Melin K et al, J Am Acad Child Adolesc Psychiatry 2020;59(2):244–253

OCD affects 1%–4% of children and adolescents and can be chronically debilitating in 40%–60% of cases.

The well-known Pediatric OCD Treatment Study (POTS) published in 2004 showed that CBT and sertraline had comparable benefits over 12 weeks of treatment; however, it left us with questions about whether we should continue CBT or recommend pharmacotherapy for youth who do not respond to CBT in 12–16 sessions. Also, given the chronic course of OCD in many patients, questions persist about how treatment options compare in the long run. The current study tried to find answers to the latter.

The Nordic Long-term OCD Treatment Study (NordLOTS) enrolled 269 children and adolescents (ages 7–17 years) with OCD from clinics across Sweden, Norway, and Denmark. Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS) scores were used as inclusion criteria (> 15) and to deem subjects as responders (0–15), non-responders (16–40), or in remission (0–10).

All participants were treated with 14 weeks of manualized exposure-based CBT. Non-responders to weekly CBT (n = 64) were randomized to continued CBT (n = 28) for 10 more sessions or switched to sertraline (n = 26) titrated at 25–200 mg over 16 weeks. Subjects were followed periodically for 3 years.

After 3 years, 73% (n = 196) of kids were in remission with 24% scoring 0 on the CY-BOCS. Another 17% (n = 46) had mild symptoms (CY-BOCS 11–15). Those who responded well to initial CBT (65%, n = 177) continued to do well with minimal additional intervention.

Non-responders to initial CBT had significantly more severe OCD at baseline (CY-BOCS 26.4 vs 23.8, p < 0.001) but showed comparable improvement at 2-year follow-up (CY-BOCS 9.6 vs 5.6, p < 0.001) and caught up with responders at 3-year follow-up (CY-BOCS 5.0 for both). Surprisingly, non-responders to initial CBT did equally well with continued CBT vs a switch to sertraline.

Only 27% of the participants had a chronic course in this study (17% mild and 10% moderate to severe), perhaps due to early initiation of quality treatment (average 1.2 years after onset of symptoms).

CCPR’s Take
Quality manualized exposure-based CBT remains an excellent approach for pediatric OCD, but some kids need continued treatment for adequate response. In contrast to adult studies showing that CBT benefits may endure better than medication treatment once treatment ends (Ponniah K et al, J Obsessive Compuls Relat Disord 2013;2(2):207–218), this study shows that in kids, SSRIs are just as effective for those who don’t benefit from or cannot access CBT. Either treatment works better when started earlier and coupled with ongoing monitoring. With good treatment, long-term prognosis for pediatric OCD is excellent.
Child Psychiatry
KEYWORDS cognitive_behavioral_therapy obsessive-compulsive-disorder serotonin-specific-reuptake-inhibitors
Pavan Madan, MD

Dealing With Side Effects of SSRIs

More from this author
www.thecarlatreport.com
Issue Date: March 12, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Clinical Complexity With Children and Adolescents, CCPR, Jan/Feb/Mar 2021
Prescribing to Children of Divorce
Treating Pandemic-Associated Trauma in Children and Adolescents
Long-Term Treatment Response in Pediatric OCD
New Canadian Eating Disorders Guidelines
Melatonin for Sleep-Onset Insomnia
The MTA Turns 21: Implications for ADHD Treatment
Note From the Editor-in-Chief
Cultural Competence: Impact on Clinical Care
Pharmacogenetics: Not Quite Ready for Prime Time?
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    (PRE-ORDER) Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto52138604.jpg
    Child Psychiatry

    Readily Available and Easily Abused Over-the-Counter Medications

    Reviewing four commonly abused substances that are legally available for purchase: Dextromethorphan, antihistamines, pseudoephedrine, and Kratom.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.